PUBLISHER: The Business Research Company | PRODUCT CODE: 1578726
PUBLISHER: The Business Research Company | PRODUCT CODE: 1578726
Human chorionic gonadotropin (hCG) is a hormone produced during pregnancy by the placenta shortly after embryo implantation in the uterus. It is essential for sustaining pregnancy by stimulating the corpus luteum in the ovary to produce progesterone, which maintains the uterine lining and prevents its breakdown.
The primary technologies for producing hCG are natural source extraction and recombinant technology. Recombinant technology involves combining DNA fragments from various organisms to create new genetic combinations. hCG is used in treating female infertility, oligospermia, male hypogonadism, and other conditions. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by fertility clinics, research institutions, and other users.
The human chorionic gonadotropin market research report is one of a series of new reports from The Business Research Company that provides human chorionic gonadotropin market statistics, including human chorionic gonadotropin industry global market size, regional shares, competitors with a human chorionic gonadotropin market share, detailed human chorionic gonadotropin market segments, market trends, and opportunities, and any further data you may need to thrive in the human chorionic gonadotropin industry. This human chorionic gonadotropin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human chorionic gonadotropin market size has grown strongly in recent years. It will grow from $0.87 billion in 2023 to $0.95 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to several factors, the rising prevalence of hypogonadism among the elderly, increased awareness of hCG among healthcare professionals and patients, growing popularity of fertility tourism, an expanding elderly population, and enhanced affordability and improvements in healthcare facilities.
The human chorionic gonadotropin market size is expected to see strong growth in the next few years. It will grow to $1.31 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period is driven by factors such as the rising incidence of infertility, the increasing prevalence of polycystic ovary syndrome, higher rates of female infertility, and the growing use of hCG in veterinary medicine. Key trends for this period include advancements in pregnancy detection, new drug formulations, integration of technology, emphasis on research and development, and ongoing product innovation.
An increasing rate of infertility is anticipated to propel the growth of the human chorionic gonadotropin (hCG) market in the coming years. Infertility, defined as the inability to conceive after at least one year of consistent, unprotected intercourse, is on the rise. Contributing factors include delayed childbearing, lifestyle changes, environmental exposures, and medical conditions. Human chorionic gonadotropin (hCG) is utilized in infertility treatments to stimulate ovulation in women and support testosterone production in men, facilitating egg release and improving fertility outcomes. For instance, in April 2023, the World Health Organization reported that infertility affects approximately 17.5% of the adult population, or roughly one in six people globally, underscoring the urgent need for accessible, high-quality fertility care. Consequently, the rising infertility rate is driving the growth of the human chorionic gonadotropin market.
Key players in the human chorionic gonadotropin market are focusing on the development of innovative products, such as pregnancy detection kits, to enhance diagnostic accuracy, improve patient outcomes, and broaden market reach. Pregnancy detection kits are designed to confirm pregnancy by detecting human chorionic gonadotropin (hCG) in the body. For example, in June 2022, Proov, a US-based medical equipment manufacturer, introduced new hCG tests for early pregnancy detection, enabling women to verify pregnancy up to six days before their expected period. These tests identify hCG in urine with a reliability rate exceeding 99%, providing a dependable and accessible method for women to monitor their pregnancy status earlier than traditional tests and make informed reproductive health decisions.
In September 2023, Lupin Limited, an India-based pharmaceutical company, acquired five brands from Menarini for an undisclosed sum. This acquisition aims to expand Lupin's portfolio and strengthen its position in key therapeutic areas by integrating five established brands from Menarini. Menarini Group, an Italy-based pharmaceutical and diagnostics company, offers services related to human chorionic gonadotropin (hCG).
Major companies operating in the human chorionic gonadotropin market are Pfizer Inc., Merck & Co Inc., Novartis AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Janssen Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Menarini Group, Cipla Limited, Hikma Pharmaceuticals plc, Ferring Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Lupin Limited, Shenzhen Hepalink Pharmaceutical Group Co. Ltd., Scripps Laboratories Inc., Aspen Pharmacare Holdings Limited, Corona Remedies Pvt Ltd., Sanzyme Private Limited, Biocare Medical LLC, Lee BioSolutions Inc., MyBioSource Inc.
North America was the largest region in the human chorionic gonadotropin market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human chorionic gonadotropin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the human chorionic gonadotropin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The human chorionic gonadotropin market includes revenues earned by entities by providing services such as fertility treatments, hormone level monitoring, assisted reproductive technologies (ART), and pregnancy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Human Chorionic Gonadotropin Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on human chorionic gonadotropin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for human chorionic gonadotropin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human chorionic gonadotropin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.